Human aging and the GH-IGF-I axis

The activity of the GH-IGF-I axis undergoes an age-related reduction and in the elderly both spontaneous GH secretion and IGF-I levels are frequently low overlapping with those usually recorded in GH deficient patients. Hypoactivity of the GH-IGF-I axis could explain age-related changes in body comp...

Full description

Saved in:
Bibliographic Details
Published inJournal of pediatric endocrinology & metabolism : JPEM Vol. 9 Suppl 3; p. 271
Main Authors Ghigo, E, Arvat, E, Gianotti, L, Ramunni, J, DiVito, L, Maccagno, B, Grottoli, S, Camanni, F
Format Journal Article
LanguageEnglish
Published Germany 01.06.1996
Subjects
Online AccessGet full text
ISSN0334-018X

Cover

More Information
Summary:The activity of the GH-IGF-I axis undergoes an age-related reduction and in the elderly both spontaneous GH secretion and IGF-I levels are frequently low overlapping with those usually recorded in GH deficient patients. Hypoactivity of the GH-IGF-I axis could explain age-related changes in body composition, function and metabolism, as also indicated by evidence that treatment with rhGH reverses these alterations. The mechanisms underlying the hypoactivity of the GH-IGF-I axis in the aged likely include changes in nutrition and lifestyle, e.g. reduction of physical exercise. However, alterations of neurohormonal hypothalamic control of GH secretion, including reduced activity of GHRH-secreting neurons and somatostatinergic hyper-activity, seem to play a major role. The exaggerated somatostatinergic hyperactivity could be due, in turn, to the impairment of cholinergic activity found in the aging brain. Age-related variations in the activity of other neurotransmitters, such as catecholamines, amino acids, e.g. arginine, neuropeptides, e.g. galanin and/or a putative natural GHRP-like ligand, could play a key role in causing the reduced activity of the GH-IGF-I axis. It is still unclear whether it is of benefit to restore GH secretion in aging. As the pituitary GH releasable pool is preserved in the elderly, it would be more appropriate to increase GH by GH secretagogues such as the new synthetic GH-releasing peptides (GHRPs) or non-peptidyl GHRP mimetics which are active even with oral administration.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
ISSN:0334-018X